###begin article-title 0
Thrombotic genetic risk factors and warfarin pharmacogenetic variants in Sao Miguel's healthy population (Azores)
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 271 274 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 284 287 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 301 307 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 406 413 406 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 433 440 433 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 557 560 557 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 563 566 563 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 583 588 583 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
The Azorean population presents the highest standardized mortality rate for cardiovascular diseases (CVD) when compared to mainland Portugal and other populations. Since thrombosis is a common cause of CVD, we assessed four polymorphisms in three thrombotic risk genes - F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C), in 469 healthy blood donors from Sao Miguel Island (Azores). We also analysed the CYP2C9 (C430T, A1075C) and VKORC1 (G1639A) variants in fifty-eight individuals with predisposition to thrombosis (possessing at least one variation in F5 or F2 genes and one in MTHFR) to evaluate their warfarin drug response genetic profiles.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 238 239 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 241 243 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 359 361 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 363 365 361 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2</italic>
###xml 367 373 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 844 850 842 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 870 876 868 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 894 901 892 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 1052 1059 1050 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 1063 1070 1061 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
Among the 469 individuals, the data showed that thrombotic risk allele frequencies - 1691A (4.9%), 20210A (1.8%), 677T (41.7%) and 1298C (24.8%) - were similar to other Caucasians, but significantly different from mainland Portuguese (chi2, p < 0.001). The combined analysis of these variants identified twenty-two different genetic profiles (genotype order: F5, F2, MTHFR C677T and A1298C). Complete homozygosity for all wild-type alleles (GG GG CC AA) was present in 11.7%, being GG GG CT AA (22.4%) the most frequent profile. The results also demonstrated that 12.4% (58 out of 469) of Sao Miguel islanders have increased genetic predisposition to thrombosis. Subsequently, we evaluated these individuals for their warfarin response genetic profiles. The data showed that seven out of fifty-eight individuals are poor metabolizers (two with CYP2C9*2/*2 and five with CYP2C9*2/*3 genotypes). VKORC1 polymorphism analysis identified twelve individuals (20.7%) with AA genotype, who probably will require lower doses of warfarin. The joint analysis of CYP2C9 and VKORC1 revealed that 79.3% (46 out of 58) of the individuals carry at least one polymorphism in these genes. Within these, twenty-five individuals (43.1%) need intermediate and/or low doses of warfarin, if treatment is started.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 365 372 <span type="species:ncbi:9606">patient</span>
The present study demonstrated, for the first time, that Sao Miguel, and possibly the Azores population, shows significant differences on allele frequencies of thrombotic risk factors when compared to mainland Portugal. This research constitutes a primary approach for future studies on CVD, as well as for the implementation of warfarin dosing protocols using the patient's genotypic information.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 492 494 492 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 703 705 703 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 831 832 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 854 861 854 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 862 863 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 879 881 879 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2</italic>
###xml 1009 1012 1009 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 1203 1204 1203 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1292 1297 1292 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 1350 1351 1350 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1531 1532 1531 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1676 1677 1676 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1700 1707 1700 1707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1708 1709 1708 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1867 1874 1867 1874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1875 1877 1875 1877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1464 1472 <span type="species:ncbi:9606">patients</span>
Cardiovascular diseases (CVD) are complex disorders that include dysfunctional conditions of the heart, arteries and veins. Within these diseases, thrombosis is the third most common cardiovascular event worldwide [1]. It can derive from: i) genetic factors; ii) acquired changes in the clotting mechanism; and iii) more commonly, interaction between the two factors described above [2-4]. The main hereditary form of thrombosis is caused by the G1691A variation in the factor V Leiden gene (F5; 1q23), resulting in resistance to activated protein C (APC). In the coagulation biochemical pathway, APC prevents blood clots from growing extensively large, by inactivating coagulation factor V (encoded by F5). The G1691A variation may increase the risk for thrombosis by 8 and 91 in heterozygous and homozygous states, respectively [5]. According to Poort et al. [6], prothrombin (F2; 11p11-q12) represents the second most important inherited thrombotic risk factor. A single base substitution (G20210A) in the F2 3'-untranslated region causes elevated plasma prothrombin levels. The same authors reported a 2.8-fold increase risk for venous thrombosis in heterozygous and homozygous variant individuals [6]. Other reported gene involved in thrombosis, the methylenetetrahydrofolate reductase (MTHFR; 1p36.3), includes two variants - C677T and A1298C [7]. The 677T alters the protein's folate binding site and lowers the enzymatic activity of MTHFR. As consequence, patients have elevated plasma levels of total homocysteine (tHcy) [8]. The 1298C variant also decreases the enzymatic activity of MTHFR, which is more pronounced in homozygous variant than in heterozygous state [8]. According to Heijer et al. [9], individuals with the 677TT genotype show a 15% (OR = 1.1; 95% CI = 1.0-1.3) increased risk for venous thromboembolism (VTE) in Europe. Additionally, Klerk et al. [10] reported an OR of 1.3 (95% CI = 1.1-1.5) for the 677CT genotype.
###end p 9
###begin p 10
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 595 602 595 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 628 635 628 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 898 904 898 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 938 944 938 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 975 981 975 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 1000 1006 1000 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 1188 1190 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1256 1263 1256 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 1433 1435 1433 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1445 1452 1445 1452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1453 1455 1453 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1465 1472 1465 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
The genetic characterization of the individual's potential risk for developing thrombosis and response to drugs is essential in clinical follow-ups, as well as for medical prescription. Warfarin is one of the most widely used anticoagulant drug, which requires a thorough risk-benefit analysis since the dose prescribed should avoid hemorrhagic complications and achieves suppression of thrombosis [11]. The administrated drug is a racemic mixture of S- and R-enantiomers, having S- the majority of the therapeutic effect [12]. Warfarin pharmacogenetic studies demonstrated that variants in the CYP2C9 (Cytochrome P450 2C9) and VKORC1 (Vitamin K epoxide reductase complex subunit 1) genes account for approximately 50-60% of drug dosing variability [13,14]. Cytochrome P450 2C9 is the major enzyme responsible for metabolising the active S-enantiomer [12]. Although there are many polymorphisms in CYP2C9, the most frequent variants are: CYP2C9*1 (Arg144/Ile359, wild-type), CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu). These last two are associated with decreased metabolic efficiency of the CYP2C9 enzyme and increased risk of bleeding when administrated initial dosages of warfarin [15]. A G>A variation at position 1639 in the promoter region of the VKORC1 gene results in decreased mRNA transcription and increased sensitivity to warfarin inhibition of hepatic synthesis of functional vitamin K-dependent coagulation factors [13]. Rieder et al. [13] studied VKORC1 polymorphisms and classified individuals according to warfarin dose requirements into distinct groups: high (GG), intermediate (GA) and low (AA).
###end p 10
###begin p 11
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 360 362 360 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 364 367 364 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 550 557 550 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 561 568 561 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
The Azores population presents the highest standardized mortality rate caused by CVD when compared to mainland Portugal (Portuguese General Directorate of Health) [16] and other populations. Since thrombosis is a known cause of CVD, the present research aims to assess, in the Sao Miguel healthy population, the allelic variants and genotypes of three genes - F5, F2 and MTHFR - involved in blood clot formation. Moreover, in the individuals with predisposition to thrombosis, we evaluated the pharmacogenetic profile for warfarin, by characterizing CYP2C9 and VKORC1 polymorphisms. This information is important for the implementation of warfarin pre-prescription genotyping with the goal of performing individualized treatment.
###end p 11
###begin title 12
Materials and methods
###end title 12
###begin title 13
Population sample
###end title 13
###begin p 14
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 432 435 432 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 445 448 445 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 645 648 645 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 659 665 659 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 711 714 711 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 725 731 725 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 775 777 775 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 779 782 779 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 786 792 786 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 990 997 990 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 1001 1008 1001 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
The population sample comprised a group of 469 Sao Miguel Island blood donors from the anonymized Azorean DNA bank located in the main Hospital of Azores archipelago, Portugal [17]. Sao Miguel, the largest island in this archipelago, has 131,609 inhabitants (54.4% of the Azoreans; 2001 Census, Portugal National Institute of Statistics) [18]. In this group we analysed four polymorphisms in three thrombotic predisposition genes - F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C). After evaluating the genetic variants in the aforementioned genes, we selected a subset of individuals who met one of the following criteria: 1. one variant in F5 and one in MTHFR (fourty-three individuals); 2. one variant in F2 and one in MTHFR (fifteen individuals) and 3. one variant in F5, F2 and MTHFR (zero individuals). These criteria were chosen to restrict the sample to individuals who would have a higher genetic risk for a thrombotic event, and hence fifty-eight individuals were analysed for CYP2C9 and VKORC1 polymorphisms.
###end p 14
###begin title 15
###xml 14 17 14 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
Genotyping of F5 and MTHFR polymorphisms
###end title 15
###begin p 16
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 34 35 34 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 179 182 179 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mnl</italic>
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hinf</italic>
###xml 195 198 195 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
###xml 291 294 291 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 349 354 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
F5 and MTHFR polymorphisms (Table 1) were evaluated by polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP), using three different restriction enzymes: MnlI, HinfI and MboII (New England Biolabs, Beverly, MA, USA). The genotyping protocol for the detection of the F5 polymorphism and MTHFR variants was adapted from Kumar et al. [19] and Skibola et al. [20], respectively.
###end p 16
###begin p 17
Main characteristics of the seven genetic variants analysed in this study
###end p 17
###begin p 18
NA - not applicable; UTR - untranslated region.
###end p 18
###begin title 19
###xml 14 16 14 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2</italic>
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
Genotyping of F2, CYP2C9 and VKORC1 polymorphisms
###end title 19
###begin p 20
###xml 27 29 27 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2</italic>
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 56 57 56 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
The genetic tests used for F2, CYP2C9 and VKORC1 (Table 1) were PTH StripAssaytrade mark and PGX-Thrombo StripAssaytrade mark kits (ViennaLab-Labordiagnostika GmbH-Austria), according to the manufacturer's recommendations. These assays are based on reverse hybridization system, using biotin-labelled amplification products to a parallel array of allele-specific oligonucleotides immobilized on a membrane test strip.
###end p 20
###begin title 21
Statistical Analysis
###end title 21
###begin p 22
###xml 459 461 457 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 500 502 498 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Allele frequencies were obtained by direct count. Hardy-Weinberg equilibrium was calculated using the Arlequin software v.3.20. This software was used to assess maximum likelihood genetic profiles for thrombotic risk factors, through the expectation maximization algorithm, an iterative procedure from multilocus genotype data with unknown gamete phase. Allele and genotype frequencies were compared between Sao Miguel islanders and mainland Portuguese by chi2 test using the SPSS software v.17.0. A p < 0.05 was considered statistically significant.
###end p 22
###begin title 23
Results
###end title 23
###begin title 24
Allele and genotype frequencies of thrombotic genetic risk factors
###end title 24
###begin p 25
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 236 239 236 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 419 422 419 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 703 709 703 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
Allele and genotype frequencies of F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C) polymorphisms were assessed in 469 healthy individuals from Sao Miguel Island, Azores (Table 2). All markers were in Hardy-Weinberg equilibrium. The F5 variant 1691A frequency was 4.9%, whereas the heterozygous genotype (1691GA) was present at 9.8% (fourty-six individuals). We did not detect 1691AA individuals. The results on the F2 analysis show an allele frequency of 1.8% for the 20210A variant. Although this polymorphism is also uncommon in other populations, one homozygous variant individual (0.2%) and fifteen heterozygous (3.2%) were observed in the present study. The frequency of the variant alleles in MTHFR (677T and 1298C) was 41.7 and 24.8%, respectively. Overall, 17.9% are 677TT (eighty-four individuals), and 6.0% present the 1298CC genotype (twenty-eight individuals).
###end p 25
###begin p 26
Allele and genotype frequencies for thrombotic risk factors and for warfarin pharmacogenetic variants in Sao Miguel population
###end p 26
###begin p 27
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a Number of chromosomes
###end p 27
###begin p 28
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
b Number of alleles
###end p 28
###begin p 29
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
c*1*1 (430CC/1075AA), *1*2 (430CT/1075AA), *1*3 (430CC/1075AC), *2*2 (430TT/1075AA), *2*3 (430CT/1075AC) and *3*3 (430CC/1075CC)
###end p 29
###begin p 30
###xml 42 44 42 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 46 49 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 336 342 336 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 537 538 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 540 542 538 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 634 641 632 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 642 644 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 745 748 743 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 758 761 756 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 774 780 772 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 901 903 899 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 904 909 902 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 938 940 936 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2</italic>
###xml 941 946 939 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 993 994 991 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1023 1024 1021 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Twenty-two different genetic profiles for F5, F2 and MTHFR (order in genotype profile) were observed in Sao Miguel's population (Figure 1). The frequency of individuals who present a wild-type genotype for all polymorphisms (GG GG CC AA; 11.7%) was almost half of the major profile (GG GG CT AA; 22.4%), differing in heterozygosity for MTHFR 677CT. Statistical analysis of the combined genotypes demonstrated that there is no significant difference between the present distribution and the hypothetical obtained by Arlequin software (chi2, p = 0.99). No heterozygous or homozygous profiles for all four variants were observed. Almawi et al. [21], reported an OR of 10.5 (95% CI = 4.3-25.3) or 6.3 (95% CI = 1.5-26.0) for joint occurrence of the F5 G1691A or F2 G20210A with MTHFR 677TT genotype, respectively, enhancing the risk for deep vein thrombosis (DVT). Based on this criterion, fifteen (3.2%, F5/MTHFR) and two individuals (0.4%, F2/MTHFR) have higher risk for DVT development (Figure 1 - asterisk character; Table 3 - bold characters). In general, the joint analysis of all four variants demonstrated that 12.4% of the total sample (58 out of 469) has increased predisposition to thrombosis development.
###end p 30
###begin p 31
###xml 49 51 49 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 53 56 53 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 0 92 0 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Combined genotypes for thrombotic risk factors &#8211; <italic>F5</italic>, <italic>F2 </italic>and <italic>MTHFR </italic>&#8211; in S&#227;o Miguel population</bold>
###xml 293 296 293 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 306 309 306 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 322 328 322 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
Combined genotypes for thrombotic risk factors - F5, F2 and MTHFR - in Sao Miguel population. Twenty-two different genetic profiles were obtained. Bold characters (blue and black) indicate nucleotide changes compared to the wild-type allele. The asterisk (*) represents the combination of the F5 G1691A or F2 G20210A with MTHFR 677TT genotype. Blue bars correspond to the subset of fifty-eight individuals with genetic predisposition to thrombosis selected for warfarin pharmacogenetic study.
###end p 31
###begin p 32
###xml 112 115 112 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 118 121 118 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 138 143 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
Warfarin pharmacogenetic profile obtained in the fifty-eight individuals, carriers of at least one variation in F5 or F2 genes and one in MTHFR
###end p 32
###begin p 33
###xml 118 121 118 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 131 134 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 147 153 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
Italic characters indicate nucleotide changes considering the wild-type allele and in bold illustrate carriers of the F5 G1691A or F2 G20210A with MTHFR 677TT genotype conferring high thrombotic risk.
###end p 33
###begin p 34
###xml 78 80 78 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 169 170 169 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 179 182 179 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 295 298 295 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 451 457 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
The comparison of allele frequencies of the thrombotic genetic risk factors - F5, F2 and MTHFR - in different populations, including Sao Miguel, is depicted in Figure 2[6,22-38]. F5 G1691A varies from as low as 0.67% (African-American) to 4.9% (Sao Miguel Island). This trend is not evident for F2 G20210A, where the values present a lower range, from 0.3% for African-American to 2.6% for Spanish. African populations showed the lowest frequency for MTHFR variants. Taken together, the results demonstrate that, in Sao Miguel, the frequencies for all polymorphisms were similar to those found in Caucasians.
###end p 34
###begin p 35
###xml 52 55 52 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 65 68 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 0 152 0 152 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Allele frequencies of the thrombotic risk factors &#8211; <italic>F5 </italic>(G1691A), <italic>F2 </italic>(G20210A) and <italic>MTHFR </italic>(C677T, A1298C) &#8211; in different populations, including S&#227;o Miguel</bold>
Allele frequencies of the thrombotic risk factors - F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C) - in different populations, including Sao Miguel.
###end p 35
###begin title 36
Frequencies of pharmacogenetic variants in individuals with genetic predisposition to thrombosis
###end title 36
###begin p 37
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 132 135 132 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 181 188 181 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 298 299 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 546 553 546 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
In order to understand warfarin pharmacogenetic profile in the fifty-eight individuals, carriers of at least one variation in F5 or F2 genes and one in MTHFR, we studied CYP2C9 and VKORC1 gene polymorphisms. The allele frequencies for CYP2C9*2 and CYP2C9*3 were 15.5 and 10.3%, respectively (Table 2). Five genotypes were observed: CYP2C9*1/*1 (60.3%), CYP2C9*1/*2 (15.5%), CYP2C9*1/*3 (12.1%), CYP2C9*2/*2 (3.5%) and CYP2C9*2/*3 (8.6%). The data indicate that 39.7% will require intermediate and/or low warfarin maintenance doses. Regarding the VKORC1 gene (G1639A), we identified twenty (34.5%) wild-type individuals, twenty-six (44.8%) heterozygous and twelve (20.7%) homozygous variant, corresponding to an allele frequency of 43.1% for 1639A (Table 2). These results suggest that 65.5% need intermediate and/or low doses of warfarin.
###end p 37
###begin p 38
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 221 228 221 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 232 239 232 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
The majority of individuals with a genetic predisposition to thrombosis (79.3%, 46 out of 58) carry at least one polymorphism in the genes involved in the metabolism of warfarin (Table 3). Moreover, the joint analysis of CYP2C9 and VKORC1 identified a total of thirty-three (57%) individuals that probably will require high doses of warfarin (genotypes: *1*1-GG-->twelve individuals, *1*1-GA-->fourteen, *1*2-GG-->four and *1*3-GG-->three), and eight (13.8%) will need lower doses (genotypes: *1*2-AA-->one individual, *1*3-AA-->one, *2*2-GA-->two, *2*3-GA-->one and *2*3-AA-->three). The remaining seventeen individuals (29.3%) present one of the following genotypes: *1*1-AA-->nine individuals, *1*2-GA-->four, *1*3-GA-->three and *2*3-GG-->one, where all of them will possibly necessitate intermediate doses. In summary, twenty-five individuals (43.1%) will need intermediate and/or low doses of warfarin, if treatment is started.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 418 421 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 818 821 818 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 847 854 847 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 979 982 979 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 983 984 983 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 991 994 991 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 1074 1076 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
In the general population, individuals may develop thrombosis due to multiple risk factors, acquired and genetic. Clearly, acquired factors (smoking, high cholesterol, obesity, etc.) are more frequent and combined with a genetic predisposition further enhance the risk of a thrombotic event. In the present study, the results obtained from 469 Sao Miguel healthy individuals demonstrate that approximately 5% have the F5 1691A allele, the most common hereditary risk factor. Although the frequency found for Sao Miguel is higher than mainland Portuguese, 1% [22], we did not detect homozygous variant individuals. Nonetheless, the data suggest that Sao Miguel islanders have an increased predisposition to thrombosis and, most probably for CVD. Another inherited cause of thrombosis is the G20210A polymorphism in the F2 gene. According to Bosler et al. [39], this variant is weak but a consistent risk factor for DVT and for development of CVD, although to a lesser degree than F5 [4]. The F2 results show a lower frequency, 1.8%, when compared to mainland Portugal, 2.5% [22].
###end p 40
###begin p 41
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 346 353 346 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 401 404 401 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
The most general form of genetic hyperhomocysteinemia results from the MTHFR C677T variant, which has a relatively high frequency throughout the world and is considered a low risk factor for vascular diseases [9]. In Sao Miguel population, MTHFR 677T shows an allelic frequency of 41.7%, very similar to Europeans (Figure 2). According to Almawi et al. [21], MTHFR 677TT genotype when associated with F5 or F2 increases the risk of DVT [20]. Based on these genotypes, the data suggests that 3.6% (seventeen individuals) of the Sao Miguel Island population may have higher risk for developing a thrombotic event. Regarding the 1298C variant, the results were in agreement with those reported by other studies (Figure 2), where the polymorphism is also common. We can hypothesise that if the 1298CC individuals have higher plasma homocysteine levels, they will present an enhanced risk for thrombosis.
###end p 41
###begin p 42
###xml 321 322 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 324 326 322 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
The joint analysis of all variants demonstrated that 12.4% of the total sample (58 out of 469) has increased predisposition to thrombosis development. In addition, comparison of allele frequencies for all thrombotic risk factors between Sao Miguel and mainland Portugal revealed statistically significant differences (chi2, p < 0.001). Family-based investigation tends to have biased relative risk estimation, because oversampling of affected individuals is normally present. Therefore, the genetic characterization of disease variants in the general population is important to correct this potential bias. Consequently, the present research will aid the clinical follow-ups of patients with recurrent thrombotic events.
###end p 42
###begin p 43
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 460 467 460 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 585 588 585 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5 </italic>
###xml 591 594 591 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2 </italic>
###xml 611 616 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 690 696 690 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 728 734 728 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 741 747 741 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 801 807 801 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
In today's medicine, the association between pharmacogenetics and drug therapy represents an important tool to treat or control complex diseases. Drug treatment is based on the assumption that a particular dose will yield a predefined blood concentration in circulation and, thereby, establish the desired therapeutic effect [40]. Recent investigations clearly demonstrate an association between warfarin dose requirements and genetic variations in CYP2C9 and VKORC1 [14]. Here, we analysed 58 individuals with genetic predisposition to thrombosis defined by at least one variation in F5 or F2 genes and one in MTHFR. The results obtained show that approximately 60.3% present the genotype CYP2C9*1/*1, while the remaining have CYP2C9*2 and CYP2C9*3 variants. The presence of two copies of the active CYP2C9*1 alleles represents the normal metabolic capacity - extensive metabolizers (EMs) -, indicating that individuals with this genotype require the highest warfarin maintenance doses [41].
###end p 43
###begin p 44
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 444 450 444 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 457 463 457 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 829 835 829 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 855 861 855 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 884 885 884 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1083 1090 1083 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 1330 1332 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
Considering Sao Miguel islanders with genetic predisposition to thrombosis, the data of CYP2C9*2 and CYP2C9*3 alleles demonstrate a close similarity with different European populations [42-44]. Individuals who are heterozygous (CYP2C9*1/*2 and CYP2C9*1/*3) represent a middle range of metabolic activity - intermediate metabolizers, IMs [43,44]. The results reveal that, within the fifty-eight subset, 15.5 and 12.1% are IMs, respectively. The CYP2C9*2 and CYP2C9*3 variants have less activity and metabolize warfarin more slowly. Individuals with one or two of these variations - poor metabolizers (PMs) - have an enhanced response to warfarin, as well as an increased risk of bleeding when beginning and during treatment if not genotyped previously [44]. We observed that seven out of fifty-eight individuals are PMs (two with CYP2C9*2/*2 and five with CYP2C9*2/*3 genotypes; Table 2). Detecting genetic variations in drug-metabolizing enzymes is useful for identifying individuals who may experience adverse drug reactions (ADRs) with conventional medication doses. Those who are CYP2C9 PMs may exhibit different pharmacokinetics than wild-type individuals if they are medicated with warfarin. Consequently, these individuals possibly will require non-conventional doses of drugs that need CYP2C9 enzyme for biotransformation [45].
###end p 44
###begin p 45
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 338 345 338 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 664 669 <span type="species:ncbi:9606">human</span>
###xml 1053 1060 <span type="species:ncbi:9606">patient</span>
Polymorphisms within VKORC1, a target of warfarin inhibition, may explain 23% of this drug dosage variability [13]. Rieder and colleagues [13] divided individuals into warfarin high-dose for 1639GG genotype, intermediate-dose for 1639GA and low-dose for 1639AA. This variability is attributed to the fact that the variant lies within the VKORC1 promoter, potentially resulting in decreased transcription of the gene product. In general, the results suggest that 65.5% of the fifty-eight individuals with predisposition to thrombosis will require intermediate and/or low doses of warfarin, if treatment is started. Personalized medicine relies on data based on the human genome and disease biology characterization for the development of preventive, diagnostic, and therapeutic strategies that target the underlying determinants of disease in populations with specific molecular profiles [46]. For this reason, the knowledge obtained from the pharmacogenetic profile in the Sao Miguel's general population is and will be important for the development of patient's individualized therapy, mainly for those who have difficulty to stabilize the warfarin dose.
###end p 45
###begin title 46
Conclusion
###end title 46
###begin p 47
###xml 108 115 <span type="species:ncbi:9606">patient</span>
###xml 607 614 <span type="species:ncbi:9606">patient</span>
The identification of hereditary risk factors, with appropriate clinical evaluation will allow the informed patient and physician to work together for effective management of thrombosis and prevention of subsequent thrombotic events. The present study demonstrated, for the first time, that Sao Miguel, and possibly the Azores population, shows significant differences on allele frequencies of thrombotic genetic risk factors when compared to mainland Portugal. This research constitutes a primary approach for future studies on CVD, as well as for the implementation of warfarin dosing protocols using the patient's genotypic information.
###end p 47
###begin title 48
Abbreviations
###end title 48
###begin p 49
###xml 111 117 111 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9</italic>
###xml 119 120 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 201 203 201 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F2</italic>
###xml 223 225 223 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F5</italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1</italic>
ADRs: Adverse drug reactions; APC: Activated protein C; CI: Confidence interval; CVD: Cardiovascular diseases; CYP2C9: Cytochrome P450 2C9 gene; DVT: Deep vein thrombosis; EMs: Extensive metabolizers; F2: Prothrombin gene; F5: Factor V Leiden gene; IMs: Intermediate metabolizers; MTHFR: Methylenetetrahydrofolate reductase gene; OR: Odds Ratio; PCR-RFLP: Polymerase chain reaction - restriction fragment length polymorphism; PMs: Poor metabolizers; SNP: Single nucleotide polymorphism; tHcy: Total homocysteine; VKORC1: Vitamin K epoxide reductase complex subunit 1 gene; VTE: Venous thromboembolism.
###end p 49
###begin title 50
Competing interests
###end title 50
###begin p 51
The authors declare that they have no competing interests.
###end p 51
###begin title 52
Authors' contributions
###end title 52
###begin p 53
###xml 127 133 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 180 183 <span type="species:ncbi:12202?0.5">LMV</span>
CCB and TP, contributed equally, by performing the experiments, statistical analysis and drafting the manuscript. RC genotyped MTHFR variants and PRP participated in the analysis. LMV designed the study, provided scientific orientation and revised the manuscript. All authors read and approved the final manuscript.
###end p 53
###begin title 54
Acknowledgements
###end title 54
###begin p 55
This work was supported by grants from Direccao Regional da Ciencia e Tecnologia of Azores (Ref. M1.2.1/I/002/2008). PRP is funded by grant (Ref. SFRH/BD/27453/2006) from Fundacao para a Ciencia e a Tecnologia of Portugal.
###end p 55
###begin article-title 56
Venous thrombolysis: Current perspectives
###end article-title 56
###begin article-title 57
Cardiovascular disease: prevention and control (WHO Global Strategy on Diet, Physical Activity and Health)
###end article-title 57
###begin article-title 58
Venous thrombosis, a multicausal disease
###end article-title 58
###begin article-title 59
Hereditary thrombophilia
###end article-title 59
###begin article-title 60
Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis
###end article-title 60
###begin article-title 61
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
###end article-title 61
###begin article-title 62
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
Homocysteine and MTHFR mutations. Relation to thrombosis and coronary artery disease
###end article-title 62
###begin article-title 63
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphisms in angiographically documented coronary artery disease
###end article-title 63
###begin article-title 64
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies
###end article-title 64
###begin article-title 65
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
MTHFR 677C>T polymorphism and risk of coronary heart disease. A meta-analysis
###end article-title 65
###begin article-title 66
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations
###end article-title 66
###begin article-title 67
The pharmacogenomics of warfarin
###end article-title 67
###begin article-title 68
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
###end article-title 68
###begin article-title 69
###xml 7 14 7 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GGCX </italic>
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
###end article-title 69
###begin article-title 70
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population
###end article-title 70
###begin article-title 71
Portuguese General Directorate of Health
###end article-title 71
###begin article-title 72
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human DNA bank in Sao Miguel Island (Azores): A resource for genetic diversity studies
###end article-title 72
###begin article-title 73
Portugal National Institute of Statistics
###end article-title 73
###begin article-title 74
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Low frequency of factor V Leiden and prothrombin G20210A mutations in patients with hepatic venous outflow tract obstruction in northern India: a case-control study
###end article-title 74
###begin article-title 75
Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukaemia in adults
###end article-title 75
###begin article-title 76
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis
###end article-title 76
###begin article-title 77
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Combined factor V Leiden (R506Q) and prothrombin G20210A genotyping in young patients presenting with deep venous thrombosis
###end article-title 77
###begin article-title 78
Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T and population genetics
###end article-title 78
###begin article-title 79
Factor V Leiden is associated with higher risk of deep venous thrombosis of large blood vessels
###end article-title 79
###begin article-title 80
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Racial differences in the prevalence of factor V Leiden mutation among patients on chronic warfarin therapy
###end article-title 80
###begin article-title 81
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Factor V Leiden (G1691A) and prothrombin-G20210A alleles among patients with deep venous thrombosis and in the general population from Spain
###end article-title 81
###begin article-title 82
Ethnic differences in the linkage disequilibrium and distribution of single-nucleotide polymorphisms in 35 candidate genes for cardiovascular diseases
###end article-title 82
###begin article-title 83
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Factor V leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis
###end article-title 83
###begin article-title 84
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
Prevalence of factor V Leiden, prothrombin G20210A and MTHFR C677T mutations in a Greek population of blood donors
###end article-title 84
###begin article-title 85
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR
###end article-title 85
###begin article-title 86
Frequencies of prothrombin 20210 G>A mutation may be different among races studies on Japanese populations with various forms of thrombotic disorders and healthy subjects
###end article-title 86
###begin article-title 87
5,10 - Methylenetetrahydrofolate reductase 677C>T and 1298A>C mutations are genetic determinants of elevated homocysteine
###end article-title 87
###begin article-title 88
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Genotypes of the C677T and A1298C polymorphisms of the MTHFR gene as a cause of human spontaneous embryo loss
###end article-title 88
###begin article-title 89
###xml 85 90 <span type="species:ncbi:9606">women</span>
Folate gene polymorphisms and the risk of Down syndrome pregnancies in young Italian women
###end article-title 89
###begin article-title 90
Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos
###end article-title 90
###begin article-title 91
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFD</italic>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTRR</italic>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RFC1 </italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCP2</italic>
###xml 60 65 <span type="species:ncbi:9606">human</span>
Genotype frequencies and linkage disequilibrium in the CEPH human diversity panel for variants in folate pathway genes MTHFR, MTHFD, MTRR, RFC1 and GCP2
###end article-title 91
###begin article-title 92
5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview
###end article-title 92
###begin article-title 93
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
High prevalence of MTHFR gene A1298C polymorphism in Lebanon
###end article-title 93
###begin article-title 94
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Phenotypic heterogeneity in patients with homozygous prothrombin 20210AA genotype
###end article-title 94
###begin article-title 95
Dose adjustments based on pharmacogenetic of CYP450 enzymes
###end article-title 95
###begin article-title 96
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations
###end article-title 96
###begin article-title 97
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
CYP2C9 genotypes and diclofenac, metabolism in Spanish healthy volunteers
###end article-title 97
###begin article-title 98
###xml 35 43 <span type="species:ncbi:9606">patients</span>
The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
###end article-title 98
###begin article-title 99
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2C9 </italic>
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
CYP2C9 and VKORC1 genetic polymorphism analysis might be necessary in patients with factor V Leiden and prothrombin gene G2021A mutation(s)
###end article-title 99
###begin article-title 100
Pharmacogenetics and pharmacogenomics: adverse drug reactions
###end article-title 100
###begin article-title 101
Identification of genetic factors and development of genetic risk diagnosis systems for cardiovascular diseases and stroke
###end article-title 101

